HONG KONG – Legochem Biosciences Inc. and Takeda Pharmaceutical Co. Ltd. have entered into a research collaboration and license agreement to develop antibody-drug conjugates (ADCs) in immuno-oncology, a follow-up to their deal in 2017 to evaluate the potential of next-generation ADC candidates based on Legochem's ADC linker and conjugation technology platform, Conjuall. (See BioWorld, Jan. 25, 2017.)